M. D Michaelson
NRG Oncology · Radiation Therapy Oncology Group
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name M. D Michaelson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04037254 · Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of RecurringNRG Oncology · completed · Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8 · principal investigator
- Ph1/Ph2NCT00238420 · Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder CancerNational Cancer Institute (NCI) · completed · Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NRG Oncology Network Group Operations CenterU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2014 to 2026Named on NCT04037254, NCT00238420
- Radiation Therapy Oncology GroupU10CA021661 · NCI · AMERICAN COLLEGE OF RADIOLOGY · PI Walter J. Curran · fiscal years 1985 to 2013Named on NCT00238420
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:10 UTC. The ranking covers the 200 most relevant of 60 PubMed records, and a shared surname and initials can bring in a namesake. All 60 on PubMed
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med · 20074,747 citationsRCR 108.1
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.J Clin Oncol · 20091,817 citationsRCR 43.5
- 1,498 citationsRCR 37.8
- 1,304 citationsRCR 28.8
- 983 citationsRCR 21.7
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.Lancet Oncol · 2015751 citationsRCR 22.4
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.Lancet Oncol · 2013590 citationsRCR 15.3
- 579 citationsRCR 18.9
- Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.Lancet Oncol · 2007376 citationsRCR 8.0
- Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.J Clin Oncol · 2008333 citationsRCR 7.2